Who are Propranolol and etodolac's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/propranolol-and-etodolac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Propranolol and etodolac — Competitive Intelligence Brief

Propranolol and etodolac (Propranolol and etodolac) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-blocker and NSAID combination. Area: Cardiovascular and Pain/Inflammation.

phase 3 Beta-blocker and NSAID combination Beta-adrenergic receptors (propranolol); COX-1 and COX-2 (etodolac) Cardiovascular and Pain/Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

Propranolol and etodolac (Propranolol and etodolac) — Assaf-Harofeh Medical Center. This combination uses propranolol (a beta-blocker) to reduce heart rate and blood pressure, and etodolac (an NSAID) to reduce inflammation and pain.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Propranolol and etodolac TARGET	Propranolol and etodolac	Assaf-Harofeh Medical Center	phase 3	Beta-blocker and NSAID combination	Beta-adrenergic receptors (propranolol); COX-1 and COX-2 (etodolac)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-blocker and NSAID combination class)

Assaf-Harofeh Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Propranolol and etodolac — Competitive Intelligence Brief. https://druglandscape.com/ci/propranolol-and-etodolac. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab